Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Thrombolytic therapy.

J F Cade1

  • 1Royal Melbourne Hospital, Victoria, Australia.

Blood Reviews
|March 1, 1989
PubMed
Summary
This summary is machine-generated.

Thrombolytic therapy is now more accessible and effective, especially for acute myocardial infarction, reducing mortality by 20-25%. Newer agents like recombinant tissue-type plasminogen activator offer improved safety and efficacy over older treatments such as streptokinase.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The difficulty for clinicians in prescribing the correct nutrition in critically ill patients.

Anaesthesia and intensive care·2018
Same author

Ventilation and weaning practices in Australia and New Zealand.

Anaesthesia and intensive care·2009
Same author

Update in computer-driven weaning from mechanical ventilation.

Anaesthesia and intensive care·2007
Same author

The microbiology and outcome of sepsis in Victoria, Australia.

Epidemiology and infection·2006
Same author

Blood usage in an Australian intensive care unit: have we met best practice goals?

Anaesthesia and intensive care·2005
Same author

The influence of a blood conserving device on anaemia in intensive care patients.

Anaesthesia and intensive care·2004
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
Same journal

Antibacterial, antifungal and antiviral prophylaxis and vaccination strategies in adult patients with acute myeloid and promyelocytic leukemia: An expert panel consensus from the GIMEMA group.

Blood reviews·2026
Same journal

The Lebanese national patient blood management guidelines: A new page in the medical practice.

Blood reviews·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Biotechnology

Background:

  • Thrombolytic therapy's use was historically limited by complexity and side effects.
  • Indications were primarily for major pulmonary embolism, iliofemoral venous thrombosis, and peripheral arterial occlusion.

Purpose of the Study:

  • To evaluate the expanded role and efficacy of thrombolytic therapy.
  • To compare the effectiveness and safety of new thrombolytic agents with established treatments.

Main Methods:

  • Analysis of large, multicentre trials confirming efficacy in acute myocardial infarction.
  • Clinical availability and comparison of recombinant human tissue-type plasminogen activator (rt-PA) against streptokinase.

Main Results:

Related Experiment Videos

  • Thrombolytic therapy demonstrated a 20-25% reduction in acute mortality for myocardial infarction.
  • Recombinant tissue-type plasminogen activator (rt-PA) shows greater efficacy and improved safety (less bleeding, fewer allergic reactions) compared to streptokinase.
  • Administration protocols have been simplified, eliminating the need for laboratory monitoring.

    • Conclusions:

    • Thrombolytic therapy indications have significantly expanded, particularly for acute myocardial infarction.
    • Recombinant tissue-type plasminogen activator represents a safer and more effective alternative to streptokinase.
    • Cost-effectiveness of novel thrombolytic agents remains a key consideration for widespread adoption.